
Exact Sciences Corporation EXAS
Annual report 2025
added 02-13-2026
Exact Sciences Corporation Interest Expense 2011-2026 | EXAS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Exact Sciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 18.6 M | 67.9 M | 199 M | 36.8 M | 206 K | -213 K | 6 K | 51 K | 69 K | 41 K | 21 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | -213 K | 29.3 M |
Quarterly Interest Expense Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -9.61 M | 111 K | -7.94 M | - | -7.87 M | -7.82 M | 4.11 M | - | -5.24 M | -4.51 M | -4.48 M | - | -4.68 M | -4.65 M | -4.62 M | - | 23.6 M | 22.9 M | 25.2 M | -13.7 M | 13.2 M | 12.7 M | 22 M | -11 M | 10.7 M | 8.6 M | -6.51 M | -51 K | -51 K | -54 K | -50 K | -52 K | -54 K | -53 K | 54 K | -62 K | -40 K | 107 K | 11 K | 11 K | 12 K | 13 K | 15 K | 16 K | 16 K | 18 K | 19 K | 20 K | 11 K | 5 K | 5 K | 6 K | 5 K | 5 K | 5 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.2 M | -13.7 M | 988 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | ||
|
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
26 M | $ 201.41 | -0.81 % | $ 22.4 B | ||
|
Celcuity
CELC
|
5.33 M | $ 87.87 | -0.77 % | $ 4.11 B | ||
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
106 K | $ 4.05 | -5.71 % | $ 5.39 M | ||
|
Fulgent Genetics
FLGT
|
153 K | $ 18.82 | 0.74 % | $ 579 M | ||
|
Castle Biosciences
CSTL
|
144 K | $ 20.98 | 1.35 % | $ 608 M | ||
|
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-595 K | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | ||
|
Interpace Biosciences
IDXG
|
-394 K | $ 1.64 | 2.19 % | $ 7.26 M | ||
|
Guardant Health
GH
|
-10.5 M | $ 132.35 | 0.55 % | $ 16.6 B | ||
|
CareDx, Inc
CDNA
|
524 K | $ 23.83 | 3.74 % | $ 1.27 B | ||
|
Illumina
ILMN
|
340 M | $ 166.13 | 3.21 % | $ 25.8 B | ||
|
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | ||
|
ICON Public Limited Company
ICLR
|
337 M | $ 147.98 | 1.23 % | $ 11.6 B | ||
|
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | ||
|
Mettler-Toledo International
MTD
|
68.5 M | $ 1 161.11 | 2.62 % | $ 23.9 B | ||
|
Genetic Technologies Limited
GENE
|
17.6 K | - | - | $ 7.1 B | ||
|
NeoGenomics
NEO
|
296 K | $ 11.21 | 0.54 % | $ 1.44 B | ||
|
National Research Corporation
NRC
|
-95 K | $ 18.77 | -0.11 % | $ 420 M | ||
|
Natera
NTRA
|
4.07 M | $ 216.16 | 1.93 % | $ 29.6 B | ||
|
Lantheus Holdings
LNTH
|
31.3 M | $ 104.54 | 0.02 % | $ 7.06 B | ||
|
Charles River Laboratories International
CRL
|
-22.6 M | $ 190.24 | 1.46 % | $ 9.43 B | ||
|
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.39 | 5.81 % | $ 417 M | ||
|
Medpace Holdings
MEDP
|
-5.34 M | $ 468.22 | 0.19 % | $ 13.5 B | ||
|
Myriad Genetics
MYGN
|
800 K | $ 4.32 | -0.23 % | $ 400 M | ||
|
Personalis
PSNL
|
205 K | $ 10.25 | 6.88 % | $ 915 M | ||
|
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.74 | 1.06 % | $ 25.4 B | ||
|
Senseonics Holdings
SENS
|
-23 K | $ 7.31 | 1.74 % | $ 305 M | ||
|
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
2.58 M | - | - | $ 2.69 B | ||
|
Twist Bioscience Corporation
TWST
|
-903 K | $ 81.92 | 7.55 % | $ 4.9 B | ||
|
Biomerica
BMRA
|
367 | $ 2.01 | -1.95 % | $ 4.62 M | ||
|
Laboratory Corporation of America Holdings
LH
|
224 M | $ 264.57 | -0.6 % | $ 22 B | ||
|
Thermo Fisher Scientific
TMO
|
-12 M | $ 474.8 | 1.26 % | $ 179 B | ||
|
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.67 | 2.52 % | $ 241 M | ||
|
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
38.1 M | $ 9.22 | 1.26 % | $ 2 B | ||
|
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M |